HUE056885T2 - CREB-kötõ fehérjék inhibitorai - Google Patents
CREB-kötõ fehérjék inhibitoraiInfo
- Publication number
- HUE056885T2 HUE056885T2 HUE19183741A HUE19183741A HUE056885T2 HU E056885 T2 HUE056885 T2 HU E056885T2 HU E19183741 A HUE19183741 A HU E19183741A HU E19183741 A HUE19183741 A HU E19183741A HU E056885 T2 HUE056885 T2 HU E056885T2
- Authority
- HU
- Hungary
- Prior art keywords
- cbp
- inhibitors
- binding protein
- creb binding
- creb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE056885T2 true HUE056885T2 (hu) | 2022-03-28 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE19183741A HUE056885T2 (hu) | 2018-06-29 | 2019-07-01 | CREB-kötõ fehérjék inhibitorai |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (hu) |
| EP (1) | EP3998266A1 (hu) |
| JP (3) | JP6781806B2 (hu) |
| KR (1) | KR20210025631A (hu) |
| CN (2) | CN116178369A (hu) |
| AU (2) | AU2019295790B2 (hu) |
| BR (1) | BR112020026783A2 (hu) |
| CA (1) | CA3105099A1 (hu) |
| CY (1) | CY1124762T1 (hu) |
| DK (1) | DK3587418T3 (hu) |
| ES (1) | ES2900105T3 (hu) |
| HR (1) | HRP20211698T1 (hu) |
| HU (1) | HUE056885T2 (hu) |
| IL (1) | IL279734A (hu) |
| LT (1) | LT3587418T (hu) |
| MA (1) | MA50675B1 (hu) |
| MX (1) | MX2020014303A (hu) |
| PL (1) | PL3587418T3 (hu) |
| PT (1) | PT3587418T (hu) |
| RS (1) | RS62732B1 (hu) |
| SG (1) | SG11202012767UA (hu) |
| SI (1) | SI3587418T1 (hu) |
| WO (1) | WO2020006483A1 (hu) |
| ZA (1) | ZA202100509B (hu) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116178369A (zh) * | 2018-06-29 | 2023-05-30 | 福马疗法公司 | 抑制creb结合蛋白(cbp) |
| CA3132995A1 (en) * | 2019-03-15 | 2020-09-24 | Forma Therapeutics, Inc. | Compositions and methods for treating androgen receptor positive forms of cancer |
| CA3183982A1 (en) | 2020-06-25 | 2021-12-30 | Stefanie Fluckiger-Mangual | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| BR112022026186A2 (pt) | 2020-06-25 | 2023-01-17 | Tolremo Therapeutics Ag | Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras |
| US11795168B2 (en) * | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| JP5355838B2 (ja) | 2000-11-20 | 2013-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キラルな光異性化可能な化合物 |
| CA2463136A1 (en) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Ship 1 modulators |
| US7622479B2 (en) | 2001-11-26 | 2009-11-24 | Takeda Pharmaceutical Company Limited | Bicyclic derivative, its production and use |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (hu) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| CA2562244A1 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| EP1968950A4 (en) | 2005-12-19 | 2010-04-28 | Genentech Inc | PYRIMIDINKINASEINHIBITOREN |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| AU2007249827A1 (en) | 2006-05-09 | 2007-11-22 | Colorado State University Research Foundation | Methods for treating blood disorders |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| WO2008157680A2 (en) | 2007-06-21 | 2008-12-24 | The Wistar Institute | Methods and compositions for modulating p300/cbp activity |
| CN101687815A (zh) | 2007-06-26 | 2010-03-31 | 塞诺菲-安万特股份有限公司 | 苯并咪唑和氮杂苯并咪唑的区域选择性铜催化合成 |
| JP5223864B2 (ja) | 2007-06-27 | 2013-06-26 | 大正製薬株式会社 | １１β−ＨＳＤ１阻害活性を有する化合物 |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| DK2303021T3 (en) | 2008-06-16 | 2019-04-08 | Univ Tennessee Res Found | RELATIONSHIPS FOR TREATING CANCER |
| EP2412710A4 (en) * | 2009-03-27 | 2012-08-08 | Kowa Co | CONDENSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT CONTAINING THE SAME |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| CN102459271B (zh) | 2009-04-15 | 2014-07-02 | Jw制药公司 | 回折模拟物的新化合物及其制备方法和用途 |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| WO2010138487A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | BENZOXAZEPINES AS INHIBITORS OF PI3K/m TOR AND METHODS OF THEIR USE AND MANUFACTURE |
| US9005670B2 (en) | 2010-01-05 | 2015-04-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| JP5879273B2 (ja) | 2010-03-01 | 2016-03-08 | ジーティーエックス・インコーポレイテッド | 癌を処置するための化合物 |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| DK2835131T3 (en) | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| CA2827392A1 (en) | 2011-02-24 | 2012-08-30 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| WO2014045305A1 (en) | 2012-09-21 | 2014-03-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
| EP3010917B1 (en) | 2013-06-21 | 2018-01-31 | Zenith Epigenetics Ltd. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| TW201605859A (zh) | 2013-11-14 | 2016-02-16 | 必治妥美雅史谷比公司 | 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌 |
| WO2015074081A1 (en) | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Benzopiperazine compositions as bet bromodomain inhibitors |
| EP3071203B1 (en) | 2013-11-18 | 2020-12-23 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| EP3193866A1 (en) | 2014-09-19 | 2017-07-26 | Genentech, Inc. | Use of cbp/ep300 and bet inhibitors for treatment of cancer |
| WO2016086200A1 (en) * | 2014-11-27 | 2016-06-02 | Genentech, Inc. | 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors |
| WO2016110821A1 (en) | 2015-01-08 | 2016-07-14 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| EP3454945B1 (en) | 2016-05-12 | 2022-01-19 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| EP3464270B1 (en) | 2016-05-24 | 2022-02-23 | Genentech, Inc. | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| US10617680B2 (en) * | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| DK3681885T3 (da) * | 2017-09-15 | 2024-04-15 | Forma Therapeutics Inc | Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer |
| CN116178369A (zh) * | 2018-06-29 | 2023-05-30 | 福马疗法公司 | 抑制creb结合蛋白(cbp) |
-
2019
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en active Application Filing
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 KR KR1020217002866A patent/KR20210025631A/ko active Search and Examination
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja active Pending
- 2020-12-23 IL IL279734A patent/IL279734A/en unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US20220162207A1/en active Pending
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE056885T2 (hu) | CREB-kötõ fehérjék inhibitorai | |
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| ZA201805879B (en) | Inhibitors of wdr5 protein-protein binding | |
| ZA202108443B (en) | Protein tyrosine phosphatase inhibitors | |
| EP4069212A4 (en) | HIF-2 ALPHA INHIBITORS | |
| EP3423437A4 (en) | INHIBITORS OF THE LINK BETWEEN THE WDR5 PROTEIN AND ITS LIAISON PARTNERS | |
| EP3679031A4 (en) | PROTEIN WDR5-PROTEIN INHIBITORS | |
| EP3801503A4 (en) | INHIBITORS OF SARM1 | |
| EP3906029A4 (en) | INHIBITORS OF MENIN-MLL INTERACTION | |
| IL304110A (en) | Keap1–nrf2 protein–protein interaction inhibitors | |
| IL275988A (en) | Heterocyclamino-converted triazoles as modulators of rho-related protein kinase | |
| IL284664A (en) | Multispecific binding proteins | |
| EP3801499A4 (en) | INHIBITORS OF SARM1 | |
| EP4069288A4 (en) | TREATMENT METHODS USING ILT7 BINDING PROTEINS | |
| EP3801500A4 (en) | INHIBITORS OF SARM1 | |
| IL284317A (en) | FAB pseudoproteins are multispecific binding proteins | |
| EP3801525A4 (en) | PROLYL-ARNT-SYNTHETASE INHIBITORS | |
| IL277869A (en) | Substituted propanamides as nuclease inhibitors | |
| AU2018901681A0 (en) | Inhibitors of necroptosis |